Skip to main content


Page 1 of 12

  1. The molecular mechanisms underlying development of posthemorrhagic hydrocephalus (PHH) following subarachnoid hemorrhage (SAH) remain incompletely understood. Consequently, treatment strategies tailored toward...

    Authors: Sara Diana Lolansen, Nina Rostgaard, Markus Harboe Olsen, Maud Eline Ottenheijm, Lylia Drici, Tenna Capion, Nicolas Hernandez Nørager, Nanna MacAulay and Marianne Juhler
    Citation: Clinical Proteomics 2024 21:51
  2. Estrogen receptor-positive (ER+) breast cancer accounts for two-thirds of all breast cancers, and its early and late recurrences still threaten patients’ long-term survival and quality of life. Finding candida...

    Authors: Qing Yu, Chunhua Qu, Jinliang Liang, Peiqi Chen, Kaiying Zhang, Yanji Zhang, Yuening Zhang, Zherui Li, Shaojun Liu, Zhaoshou Yang, Hongyan Sun and Anli Yang
    Citation: Clinical Proteomics 2024 21:50
  3. Understanding the interplay of the proteome and the metabolome helps to understand cellular regulation and response. To enable robust inferences from such multi-omics analyses, we introduced and evaluated a wo...

    Authors: Hagen M. Gegner, Thomas Naake, Karim Aljakouch, Aurelien Dugourd, Georg Kliewer, Torsten Müller, Dustin Schilling, Marc A. Schneider, Nina Kunze-Rohrbach, Thomas G.P. Grünewald, Rüdiger Hell, Julio Saez-Rodriguez, Wolfgang Huber, Gernot Poschet and Jeroen Krijgsveld
    Citation: Clinical Proteomics 2024 21:49
  4. Characterization of the host response in cutaneous leishmaniasis (CL) through proteome profiling has gained limited insights into leishmaniasis research compared to that of the parasite. The primary objective ...

    Authors: Nuwani H. Manamperi, Nimesha Madhushani Edirisinghe, Harshima Wijesinghe, Lakmali Pathiraja, Nishantha Pathirana, Vishmi Samudika Wanasinghe, Chamalka Gimhani De Silva, W. Abeyewickreme and Nadira D. Karunaweera
    Citation: Clinical Proteomics 2024 21:48
  5. Amyloidosis is a disease characterized by local and systemic extracellular deposition of amyloid protein fibrils where its excessive accumulation in tissues and resistance to degradation can lead to organ fail...

    Authors: Jennifer T. Aguilan, Jihyeon Lim, Sabrina Racine-Brzostek, Joshua Fischer, Cristina Silvescu, Shannon Cornett, Edward Nieves, Damodara Rao Mendu, Carlos-Madrid Aliste, Stacia Semple, Ruth Angeletti, Louis M. Weiss, Adam Cole, Michael Prystowsky, James Pullman and Simone Sidoli
    Citation: Clinical Proteomics 2024 21:47
  6. The development of breast cancer has been mainly reported in women who have reached the post-menopausal stage; therefore, it is the primary factor responsible for death amongst postmenopausal women. However, i...

    Authors: Abhishek Pant, Ashish. P. Anjankar, Sandesh Shende, Archana Dhok, Roshan Kumar Jha and Anjali Vagga Manglaram
    Citation: Clinical Proteomics 2024 21:45
  7. Tumorigenesis and progression of prostate cancer (PCa) are indispensably dependent on androgen receptor (AR). Antiandrogen treatment is the principal preference for patients with advanced PCa. However, the mol...

    Authors: Yurun Huang, Guanglin Yang, Xinpeng Yao, Yue Fang, Qiliang Lin, Menghan Zhou, Yiping Yang, Qinggui Meng, Qingyun Zhang and Shan Wang
    Citation: Clinical Proteomics 2024 21:44
  8. Multiple sclerosis (MS) is a clinically and biologically heterogenous disease with currently unpredictable progression and relapse. After the development and success of neurofilament as a cerebrospinal fluid (...

    Authors: Lincoln I. Wurtz, Evdokiya Knyazhanskaya, Dorsa Sohaei, Ioannis Prassas, Sean Pittock, Maria Alice V. Willrich, Ruba Saadeh, Ruchi Gupta, Hunter J. Atkinson, Diane Grill, Martin Stengelin, Simon Thebault, Mark S. Freedman, Eleftherios P. Diamandis and Isobel A. Scarisbrick
    Citation: Clinical Proteomics 2024 21:42
  9. Gliomas are aggressive malignant tumors, with poor prognosis. There is an unmet need for the discovery of new, non-invasive biomarkers for differential diagnosis, prognosis, and management of brain tumors. Our...

    Authors: Atefeh Ghorbani, Miyo K. Chatanaka, Lisa M. Avery, Mingyue Wang, Jermaine Brown, Rachel Cohen, Taron Gorham, Salvia Misaghian, Nikhil Padmanabhan, Daniel Romero, Martin Stengelin, Anu Mathew, George Sigal, Jacob Wohlstadter, Craig Horbinski, Katy McCortney…
    Citation: Clinical Proteomics 2024 21:41
  10. Avascular necrosis (AVN) is a medical condition characterized by the destruction of bone tissue due to a diminished blood supply. When the rate of tissue destruction surpasses the rate of regeneration, effecti...

    Authors: Soo-Eun Sung, Ju-Hyeon Lim, Kyung-Ku Kang, Joo-Hee Choi, Sijoon Lee, Minkyoung Sung, Wook-Tae Park, Young-In Kim, Min-Soo Seo and Gun Woo Lee
    Citation: Clinical Proteomics 2024 21:39
  11. Descending thoracic aortic aneurysms and dissections can go undetected until severe and catastrophic, and few clinical indices exist to screen for aneurysms or predict risk of dissection.

    Authors: Amanda Momenzadeh, Simion Kreimer, Dongchuan Guo, Matthew Ayres, Daniel Berman, Kuang-Yuh Chyu, Prediman K. Shah, Dianna Milewicz, Ali Azizzadeh, Jesse G. Meyer and Sarah Parker
    Citation: Clinical Proteomics 2024 21:38
  12. Information on the microbiome's human pathways and active members that can affect SARS-CoV-2 susceptibility and pathogenesis in the salivary proteome is very scarce. Here, we studied a unique collection of sam...

    Authors: Elena Moreno, Sergio Ciordia, Santos Milhano Fátima, Daniel Jiménez, Javier Martínez-Sanz, Pilar Vizcarra, Raquel Ron, Matilde Sánchez-Conde, Rafael Bargiela, Sergio Sanchez-Carrillo, Santiago Moreno, Fernando Corrales, Manuel Ferrer and Sergio Serrano-Villar
    Citation: Clinical Proteomics 2024 21:37
  13. Currently, no effective measures are available to predict the curative efficacy of small-cell lung cancer (SCLC) chemotherapy. We expect to develop a method for effectively predicting the SCLC chemotherapy eff...

    Authors: Zhihua Li, Junnan Chen, Bin Xu, Wei Zhao, Haoran Zha, Yalin Han, Wennan Shen, Yuemei Dong, Nan Zhao, Manze Zhang, Kun He, Zhaoxia Li and Xiaoqing Liu
    Citation: Clinical Proteomics 2024 21:35
  14. The early identification of patients at high-risk for end-stage renal disease (ESRD) is essential for providing optimal care and implementing targeted prevention strategies. While the Kidney Failure Risk Equat...

    Authors: Carlos Raúl Ramírez Medina, Ibrahim Ali, Ivona Baricevic-Jones, Moin A. Saleem, Anthony D. Whetton, Philip A. Kalra and Nophar Geifman
    Citation: Clinical Proteomics 2024 21:34
  15. COVID-19 is a complex, multi-system disease with varying severity and symptoms. Identifying changes in critically ill COVID-19 patients’ proteomes enables a better understanding of markers associated with susc...

    Authors: Maitray A. Patel, Mark Daley, Logan R. Van Nynatten, Marat Slessarev, Gediminas Cepinskas and Douglas D. Fraser
    Citation: Clinical Proteomics 2024 21:33
  16. Traumatic brain injury (TBI) often results in diverse molecular responses, challenging traditional proteomic studies that measure average changes at tissue levels and fail to capture the complexity and heterog...

    Authors: Sudipa Maity, Yuanyu Huang, Mitchell D. Kilgore, Abbigail N. Thurmon, Lee O. Vaasjo, Maria J. Galazo, Xiaojiang Xu, Jing Cao, Xiaoying Wang, Bo Ning, Ning Liu and Jia Fan
    Citation: Clinical Proteomics 2024 21:32
  17. Authors: Tomonori Kaneko, Sally Ezra, Rober Abdo, Courtney Voss, Shanshan Zhong, Xuguang Liu, Owen Hovey, Marat Slessarev, Logan Robert Van Nynatten, Mingliang Ye, Douglas D. Fraser and Shawn Shun‑Cheng Li
    Citation: Clinical Proteomics 2024 21:31

    The original article was published in Clinical Proteomics 2020 17:1

  18. Cardio-metabolic disorders (CMDs) are common in aging people and are pivotal risk factors for cardiovascular diseases (CVDs). Inflammation is involved in the pathogenesis of CVDs and aging, but the underlying ...

    Authors: Siting Wu, Yulin Li, Xue Zhao, Fu-Dong Shi and Jingshan Chen
    Citation: Clinical Proteomics 2024 21:30
  19. Adamantinomatous craniopharyngiomas (ACPs) are rare benign epithelial tumours with high recurrence and poor prognosis. Biological differences between recurrent and primary ACPs that may be associated with dise...

    Authors: Haidong Deng, Ting Lei, Siqi Liu, Wenzhe Hao, Mengqing Hu, Xin Xiang, Ling Ye, Dongting Chen, Yan Li and Fangjun Liu
    Citation: Clinical Proteomics 2024 21:29
  20. Certain demyelinating disorders, such as neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) exhibit serum autoantibodies against aquapori...

    Authors: Miyo K. Chatanaka, Lisa M. Avery, Maria D. Pasic, Shanthan Sithravadivel, Dalia Rotstein, Catherine Demos, Rachel Cohen, Taron Gorham, Mingyue Wang, Martin Stengelin, Anu Mathew, George Sigal, Jacob Wohlstadter, Ioannis Prassas and Eleftherios P. Diamandis
    Citation: Clinical Proteomics 2024 21:28
  21. Colorectal Cancer (CRC) is a prevalent form of cancer, and the effectiveness of the main postoperative chemotherapy treatment, FOLFOX, varies among patients. In this study, we aimed to identify potential bioma...

    Authors: Xi Wang, Keren Zhang, Wan He, Luobin Zhang, Biwei Gao, Ruijun Tian and Ruilian Xu
    Citation: Clinical Proteomics 2024 21:27
  22. Clinical samples are irreplaceable, and their transformation into searchable and reusable digital biobanks is critical for conducting statistically empowered retrospective and integrative research studies. Cur...

    Authors: Sandra Goetze, Audrey van Drogen, Jonas B. Albinus, Kyle L. Fort, Tejas Gandhi, Damiano Robbiani, Véronique Laforte, Lukas Reiter, Mitchell P. Levesque, Yue Xuan and Bernd Wollscheid
    Citation: Clinical Proteomics 2024 21:26
  23. Metastatic pancreatic adenocarcinoma (PDAC) is the third leading cause of cancer-related death in the United States, with a 5-year survival rate of only 11%, necessitating identification of novel treatment par...

    Authors: Jamie Randall, Allison L. Hunt, Aratara Nutcharoen, Laura Johnston, Safae Chouraichi, Hongkun Wang, Arthur Winer, Raymond Wadlow, Jasmine Huynh, Justin Davis, Brian Corgiat, Nicholas W. Bateman, John F. Deeken, Emanuel F. Petricoin, Thomas P. Conrads and Timothy L. Cannon
    Citation: Clinical Proteomics 2024 21:24
  24. Human tear protein biomarkers are useful for detecting ocular and systemic diseases. Unfortunately, existing tear film sampling methods (Schirmer strip; SS and microcapillary tube; MCT) have significant drawba...

    Authors: Robert K. Roden, Nathan Zuniga, Joshua C. Wright, David H. Parkinson, Fangfang Jiang, Leena M. Patil, Rebecca S. Burlett, Alyssa A. Nitz, Joshua J. Rogers, Jarett T. Pittman, Kenneth L. Virgin, P. Christine Ackroyd, Samuel H. Payne, John C. Price and Kenneth A. Christensen
    Citation: Clinical Proteomics 2024 21:23
  25. Plasma proteomics holds immense potential for clinical research and biomarker discovery, serving as a non-invasive "liquid biopsy" for tissue sampling. Mass spectrometry (MS)-based proteomics, thanks to improv...

    Authors: Ines Metatla, Kevin Roger, Cerina Chhuon, Sara Ceccacci, Manuel Chapelle, Pierre-Olivier Schmit, Vadim Demichev and Ida Chiara Guerrera
    Citation: Clinical Proteomics 2024 21:22
  26. Despite progress, MS-based proteomics in biofluids, especially blood, faces challenges such as dynamic range and throughput limitations in biomarker and disease studies. In this work, we used cutting-edge prot...

    Authors: Ghaith M. Hamza, Rekha Raghunathan, Stephanie Ashenden, Bairu Zhang, Eric Miele and Andrew F. Jarnuczak
    Citation: Clinical Proteomics 2024 21:21
  27. In persons with dyslipidemia, a high residual risk of cardiovascular disease remains despite lipid lowering therapy. Current cardiovascular risk prediction mainly focuses on low-density lipoprotein cholesterol...

    Authors: Esther Reijnders, Arnoud van der Laarse, L. Renee Ruhaak and Christa M. Cobbaert
    Citation: Clinical Proteomics 2024 21:19
  28. Cardiac rupture (CR) is a rare but catastrophic mechanical complication of acute myocardial infarction (AMI) that seriously threatens human health. However, the reliable biomarkers for clinical diagnosis and t...

    Authors: Jingyuan Hou, Qiaoting Deng, Xiaohong Qiu, Sudong Liu, Youqian Li, Changjing Huang, Xianfang Wang, Qunji Zhang, Xunwei Deng, Zhixiong Zhong and Wei Zhong
    Citation: Clinical Proteomics 2024 21:18
  29. Immunotherapy is applied to breast cancer to resolve the limitations of survival gain in existing treatment modalities. With immunotherapy, a tumor can be classified into immune-inflamed, excluded and desert b...

    Authors: Yeonjin Jeon, GunHee Lee, Hwangkyo Jeong, Gyungyub Gong, JiSun Kim, Kyunggon Kim, Jae Ho Jeong and Hee Jin Lee
    Citation: Clinical Proteomics 2024 21:17
  30. Presently, antibody concentration measurements for patients undergoing treatment are predominantly determined by ELISA, which still comes with known disadvantages. Therefore, our aim was to establish a targete...

    Authors: Andreas Hentschel, Gina Piontek, Rob Dahlmann, Peter Findeisen, Roman Sakson, Phil Carbow, Thomas Renné, Yvonne Reinders and Albert Sickmann
    Citation: Clinical Proteomics 2024 21:16
  31. Hypertension is an important public health priority with a high prevalence in Africa. It is also an independent risk factor for kidney outcomes. We aimed to identify potential proteins and pathways involved in...

    Authors: Melanie A. Govender, Stoyan H. Stoychev, Jean-Tristan Brandenburg, Michèle Ramsay, June Fabian and Ireshyn S. Govender
    Citation: Clinical Proteomics 2024 21:15
  32. Serum or plasma is frequently utilized in biomedical research; however, its application is impeded by the requirement for invasive sample collection. The non-invasive nature of urine collection makes it an att...

    Authors: Neha Joshi, Kishore Garapati, Vivek Ghose, Richard K. Kandasamy and Akhilesh Pandey
    Citation: Clinical Proteomics 2024 21:14
  33. SARS-CoV-2 infection triggers extensive host immune reactions, leading to severe diseases in certain individuals. However, the molecular basis underlying the excessive yet non-productive immune responses in se...

    Authors: Tomonori Kaneko, Sally Ezra, Rober Abdo, Courtney Voss, Shanshan Zhong, Xuguang Liu, Owen Hovey, Marat Slessarev, Logan Robert Van Nynatten, Mingliang Ye, Douglas D. Fraser and Shawn Shun-Cheng Li
    Citation: Clinical Proteomics 2024 21:13
  34. Mass spectrometry (MS) assays offer exceptional capabilities in high multiplexity, specificity, and throughput. As proteomics technologies continue advancements to identify new disease biomarkers, transition o...

    Authors: Chia-Li Han, Chi-Ting Lai, Aaron James Reyes, Hao-Chin Yang, Jin-Ying Lu, Shyang-Rong Shih, Kuen-Yuan Chen, Andrew N. Hoofnagle, Sung-Liang Yu, William Bocik, Tara Hiltke, Huan-Chi Chiu, Ching-Yi Wan, Henry Rodriguez, Victoria Zhang and Yu-Ju Chen
    Citation: Clinical Proteomics 2024 21:12
  35. Small incision lenticule extraction (SMILE) and femtosecond laser-assisted in situ keratomileusis (LASIK) are widely used surgical methods to correct myopia with comparable efficacy, predictability, and safety...

    Authors: Petri Mäkinen, Janika Nättinen, Ulla Aapola, Juhani Pietilä and Hannu Uusitalo
    Citation: Clinical Proteomics 2024 21:11
  36. COPD is a complex respiratory disorder with high morbidity and mortality rates. Even with the current conventional diagnostic methods, including circulating inflammatory biomarkers, underdiagnosis rates in COP...

    Authors: Sonu Das, Supriya Adiody, Jinsu Varghese, M Vanditha, Evelyn Maria and Mathew John
    Citation: Clinical Proteomics 2024 21:10
  37. Dynein axonemal intermediate chain 1 protein (DNAI1) plays an essential role in cilia structure and function, while its mutations lead to primary ciliary dyskinesia (PCD). Accurate quantitation of DNAI1 in lun...

    Authors: Hui Wang, Xiaoyan Ni, Nicholas Clark, Kristen Randall, Lianne Boeglin, Sudha Chivukula, Caroline Woo, Frank DeRosa and Gang Sun
    Citation: Clinical Proteomics 2024 21:8
  38. Omics characterization of pancreatic adenocarcinoma tissue is complicated by the highly heterogeneous and mixed populations of cells. We evaluate the feasibility and potential benefit of using a coring method ...

    Authors: Sara R. Savage, Yuefan Wang, Lijun Chen, Scott Jewell, Chelsea Newton, Yongchao Dou, Qing Kay Li, Oliver F. Bathe, Ana I. Robles, Gilbert S. Omenn, Mathangi Thiagarajan, Hui Zhang, Galen Hostetter and Bing Zhang
    Citation: Clinical Proteomics 2024 21:7
  39. Routine measurement of cancer biomarkers is performed for early detection, risk classification, and treatment monitoring, among other applications, and has substantially contributed to better clinical outcomes...

    Authors: Deborah Wenk, Charlotte Zuo, Thomas Kislinger and Lusia Sepiashvili
    Citation: Clinical Proteomics 2024 21:6
  40. The 2022 consensus statement of the European Atherosclerosis Society (EAS) on lipoprotein(a) (Lp(a)) recognizes the role of Lp(a) as a relevant genetically determined risk factor and recommends its measurement...

    Authors: Nina M. Diederiks, L. Renee Ruhaak, Fred P. H. T. M. Romijn, Mervin M. Pieterse, Nico P. M. Smit and Christa M. Cobbaert
    Citation: Clinical Proteomics 2024 21:5
  41. Although uterine serous carcinoma (USC) represents a small proportion of all uterine cancer cases, patients with this aggressive subtype typically have high rates of chemotherapy resistance and disease recurre...

    Authors: Allison L. Hunt, Nicholas W. Bateman, Waleed Barakat, Sasha C. Makohon-Moore, Tamara Abulez, Jordan A. Driscoll, Joshua P. Schaaf, Brian L. Hood, Kelly A. Conrads, Ming Zhou, Valerie Calvert, Mariaelena Pierobon, Jeremy Loffredo, Katlin N. Wilson, Tracy J. Litzi, Pang-Ning Teng…
    Citation: Clinical Proteomics 2024 21:4
  42. Protein kinases are frequently dysregulated and/or mutated in cancer and represent essential targets for therapy. Accurate quantification is essential. For breast cancer treatment, the identification and quant...

    Authors: Alexander B. Saltzman, Doug W. Chan, Matthew V. Holt, Junkai Wang, Eric J. Jaehnig, Meenakshi Anurag, Purba Singh, Anna Malovannaya, Beom-Jun Kim and Matthew J. Ellis
    Citation: Clinical Proteomics 2024 21:3
  43. Despite recent innovations in imaging and genomic screening promotes advance in diagnosis and treatment of lung adenocarcinoma (LUAD), there remains high mortality of LUAD and insufficient understanding of LUA...

    Authors: Yuqi Huang, Sheng Ma, Jun-Yu Xu, Kun Qian, Yaru Wang, Yi Zhang, Minjia Tan and Ting Xiao
    Citation: Clinical Proteomics 2024 21:2

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 2.8
    5-year Journal Impact Factor: 3.9
    Source Normalized Impact per Paper (SNIP): 0.831
    SCImago Journal Rank (SJR): 1.015

    Speed 2023
    Submission to first editorial decision (median days): 10
    Submission to acceptance (median days): 159

    Usage 2023
    Downloads: 434,196
    Altmetric mentions: 385